Cautionary note: A possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening

Journal of Clinical Rheumatology

Volumn 16, Issue 4, 2010, Pages 197-199

  Rahman, N ^a   Healy, C ^b   Flint, Stephen R ^b   Stassen, L F A ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CELECOXIB; ETANERCEPT; FOLIC ACID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PHENYLACETIC ACID DERIVATIVE; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CASE REPORT; CHEEK MUCOSA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLOSSECTOMY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MOUTH CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953166589     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181df8932     Document Type: Article

References (19)

1. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf. 2004;27:307-324.
2. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2485.
3. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135.
4. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953-956.
5. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819-836.
6. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomised, controlled trial. Arthritis Rheum. 2004;50:3432-3443.
7. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15:280-294.
8. FDA Briefing Document. Update on the TNF-alpha blocking agents. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm.
9. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum. 2007;56:1433-1439.
10. Fryrear RS II, Wiggins AK, Sangueza, et al. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol. 2004;51:1026.
11. Comte C, Guilhou JJ, Guillot B, et al. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology. 2008;217:284-285.
12. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-1450.
13. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68:1177-1183.
14. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141:861-864.
15. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.
16. IARC Monographs Working Group on Alcoholic Beverage Consumption and Ethyl Carbamate (Urethane); February 6-13, 2007. Available at: http://monographs. iarc.fr/ENG/Meetings/vol96-summary.pdf.
17. Merchant A, Husain SS, Hosain M, et al. Paan without tobacco: an independent risk factor for oral cancer. Int J Cancer. 2000;86:128-131.
18. Koch P, Balmer FA. Oral lesions and symptoms related to metals used in dental restorations: a clinical, allergological, and histologic study. J Am Acad Dermatol. 1999;41:422-430.
19. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck. 1998;20:250-265.